Viking Therapeutics, Inc. financial data

Symbol
VKTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
9920 Pacific Heights Blvd, Suite 350, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Oct 23, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.13K % +84%
Debt-to-equity 3.4 % -49.1%
Return On Equity -12.7 % +59.3%
Return On Assets -12.3 % +58%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 111M shares +11.4%
Common Stock, Shares, Outstanding 111M shares +11.4%
Entity Public Float 93.7M USD -52.2%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 111M shares +11.1%
Weighted Average Number of Shares Outstanding, Diluted 111M shares +11.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 91.2M USD +53.3%
General and Administrative Expense 42.8M USD +32.4%
Operating Income (Loss) -134M USD -45.9%
Net Income (Loss) Attributable to Parent -99.2M USD -22.6%
Earnings Per Share, Basic -0.92 USD/shares 0%
Earnings Per Share, Diluted -0.92 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 50.3M USD +35.4%
Assets, Current 937M USD +146%
Operating Lease, Right-of-Use Asset 1.11M USD -7.25%
Assets 938M USD +145%
Accounts Payable, Current 254K USD -95.6%
Liabilities, Current 25.7M USD +91.6%
Operating Lease, Liability, Noncurrent 755K USD -25.8%
Liabilities 26.4M USD +83.3%
Retained Earnings (Accumulated Deficit) -452M USD -28.1%
Stockholders' Equity Attributable to Parent 911M USD +148%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 911M USD +148%
Liabilities and Equity 938M USD +145%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.13M USD +75.1%
Net Cash Provided by (Used in) Financing Activities 606M USD +14385%
Net Cash Provided by (Used in) Investing Activities -460M USD -21019%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 111M shares +11.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -18.3M USD -31.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 36.6M USD +38.9%
Deferred Tax Assets, Valuation Allowance 119M USD +32.4%
Deferred Tax Assets, Gross 119M USD +32.1%
Operating Lease, Liability 1.24M USD -7.63%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -96.6M USD -20.8%
Operating Lease, Liability, Current 480K USD +50.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure +33.3%
Deferred Tax Assets, Operating Loss Carryforwards 26.3M USD +72%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 315K USD -20.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%